['Mirati Therapeutics', 'Bioscience', 'Halozyme', 'BofA Securities', 'Alnylam Pharmaceuticals', 'X-Chem', 'Acuitas Therapeutics', 'Enantigen Therapeutics', 'Alnylam Pharmaceuticals', 'BioLite', 'Nocimed', 'Nocimed', 'Civitas Therapeutics', 'Pediatrix Therapeutics', 'Universal Cells', 'Agility', 'the Aditx Therapeutics', 'Agility', 'Amgen', 'Acorda Therapeutics', 'Spitfire Pharma', 'Anacor Pharmaceuticals', 'Paragon Therapeutics', 'Apogee Therapeutics', 'Medexus Pharmaceuticals', 'ContentHoldings', 'Aravive', 'Seqirus', 'Vallon Pharmaceuticals', 'GRI Bio', 'the Vinbiocare Support Agreement', 'Vinbiocare&#x2019;s', 'Spectrum Pharmaceutical', 'NES Therapeutic', 'Riptide Bioscience', 'ModernaTX', 'Co', 'Papillon Therapeutics', 'BioScience', 'Astellas Pharma', 'Eidos Therapeutics', 'Description of Business BridgeBio Pharma', 'Resilience US', 'Navire Pharma', 'TheRas', 'Aspa Therapeutics', 'Cutanea Life Sciences', 'Leap Therapeutics', 'NanoHybrids', 'Toray Industries', 'Inc.\\\\n\\\\n&#160;\\\\n\\\\nViralClear\\\\nPharmaceuticals', 'CalciMedica', 'Graybug Vision', 'Mana Merger Sub', 'Miromatrix Medical', 'Lemurian', 'Kolltan Pharmaceuticals', 'BioCryst Pharmaceuticals', 'Houston Pharmaceuticals', 'Reata Pharmaceuticals', 'Reata Pharmaceuticals', 'WPD\\\\nPharmaceuticals', 'Envoy Medical', 'the Business and Basis of Presentation\\\\n\\\\n&#160;\\\\n\\\\nEnvoy Medical', 'VyGen-Bio', 'Aevitas Therapeutics', 'Pfizer', 'KSQ Therapeutics', 'Axolotl Biologix', 'Coherent NA', 'Crystal Bioscience', 'OmniAb', 'the Dianthus Therapeutics', 'OmniAb', 'Convergent Therapeutics', 'Juno Therapeutics', 'eFFECTOR Therapeutics', 'Anelixis Therapeutics', 'eGenesis', 'Iguana Merger Sub', 'Aevitas Therapeutics', 'OPKO Health', 'PureForm\\\\nGlobal', 'Medytox', 'NoveCite', 'Tulex Pharmaceuticals', 'Questcor Pharmaceuticals', 'InvaGen Pharmaceuticals', 'Sentynl Therapeutics', 'VYNE Therapeutics', 'Caelum Biosciences', 'InvaGen Pharmaceuticals', 'Sentynl Therapeutics', 'VYNE Therapeutics', 'Caelum Biosciences', 'Carna Biosciences', 'Bodor Laboratories', 'Brickell Subsidiary', 'Adare\\\\n    Pharmaceuticals', 'Integrated DNA Technologies', 'NantCell', 'Gilead Sciences', 'Crossbow Therapeutics', 'Harpoon Therapeutics', 'Fresenius Medical Care Holdings', 'Genentech', 'AxioMx', 'Safekeep', 'Inogen', 'the Paratek Pharmaceuticals', 'Gate Neurosciences', 'InCarda Therapeutics', 'ImaginAb', 'Ivantis', 'First Citizens BancShares', 'Avalon BioVentures', 'Aevitas Therapeutics', 'Combangio', 'Gryphon Digital Mining', 'Regeneron Pharmaceuticals', 'Adgero Biopharmaceuticals', 'Tarsus Pharmaceuticals', 'Navire Pharma', 'Landos BioPharma', 'Lyra Therapeutics', 'QED Therapeutics', 'OrganizationLENSAR', 'Endocyte', 'Advanced Accelerator Applications USA', 'SonoThera', 'Bausch Health Companies', 'Abbott Products', 'Liquidia Technologies', 'PACT Pharma', 'BofA Securities', 'Hercules Capital', 'Lemonaid Health', 'the Lemonaid Health', 'Research Cooperation Technologies', 'Aevitas Therapeutics', 'ORIC Pharmaceuticals', 'Array BioPharma', 'Aevitas Therapeutics', 'Merger Sub', 'as\\\\nMyMD Pharmaceuticals', 'Neubase Therapeutics', 'NKGen Biotech', 'Pfizer', 'Biotech', 'Alairion', 'Gemphire Therapeutics', 'AvenCell Therapeutics', 'Kyverna Therapeutics', 'Novartis Institutes for BioMedical Research', 'Regeneron Pharmaceuticals', 'Determination Date', 'OmniAb', 'Processa Pharmaceuticals', 'Rexahn Pharmaceuticals', 'Novartis Institutes for BioMedical Research', 'Alexandria Real Estate Equities', 'Cocrystal Pharma', 'Xenetic Biosciences', 'BioCardia', 'Marinus Pharmaceuticals', 'ResearchDx', 'Elion Oncology', 'AgonOx', 'Aevitas Therapeutics', 'Pharmaloz Manufacturing', 'ProPhase Diagnostics', 'Novant Health', 'Takeda Pharmaceuticals USA', 'Grifols Diagnostic Solutions', 'Clinigen Clinical Supplies Management', 'Protein Evolution', 'Rani Management Services', 'Organization and Nature of Business Description of Business Rani Therapeutics Holdings', 'Rani Management Services', 'Genentech', 'Roche Holdings', 'Telavant Holdings', 'Immunovant', 'Moderna Therapeutics', 'Telavant\\\\n              Holdings', 'the Hint', 'PeptiDream', 'Handok', 'ActiveSite Pharmaceuticals', 'Virpax Pharmaceuticals', 'Description of Business and Basis of PreparationOrganizationSCYNEXIS', 'Hercules Capital', 'PrognomiQ', 'name\\\\nto Shuttle Pharmaceuticals', 'Aziyo Biologics', 'SIGA Technologies', 'Zyl&#246;\\\\nTherapeutics', 'Precision Healing', 'The Catalyst Group', 'GP Nurmenkari', 'Myonexus Therapeutics', 'Thermo Fisher Scientific', 'Lacerta Therapeutics', 'Minotaur Therapeutics', 'ARIAD Pharmaceuticals', '2021&#xa0;Docklight Brands', 'Aevitas Therapeutics', 'ImmunoFree', 'New York Blood Center', 'Mirum Pharmaceuticals', 'NanoString Technologies', 'Globavir Biosciences', 'Nano Precision Medical', 'United&#160;Biomedical', 'The Broad Institute', 'Planck Aerosystems', 'Viracta Therapeutics', 'NantKwest', 'Paragon Therapeutics', 'Xencor', 'Enable Injections', 'Immunogen', 'Wales', 'Anteris Bio', 'Vivos Therapeutics', 'Altesa Biosciences', 'OPKO Health', 'Oppenheimer &amp;\\\\nCo', 'NitricGen', 'Alexion Pharmaceuticals', 'Zeno Management', 'Organization and BusinessOrganizationZentalis Pharmaceuticals', 'Jazz Pharmaceuticals']